{"id":"canakinumab","rwe":[],"_fda":{"id":"7e8f9d55-ff6d-cbe7-e053-2a91aa0a382e","set_id":"0fd0dcef-79c6-4489-a533-996aa5331d9c","openfda":{"nui":["N0000185375","N0000175629","N0000184306","N0000185001","M0000728","M0016962","M0516536"],"upc":["0317089296188"],"unii":["2P3VWU3H10","KK0Z92II8M","ML4QRZ1HCL","O80TY208ZW","WQZ3G9PF0H","37CQ2C7X93","T7S323PKJS","7M867G6T1U","YF70189L0N","8R564U2E1P","2S713A4VP3","6EC706HI7F","269XH13919","308LM01C72","2510RH3I89"],"route":["ORAL"],"spl_id":["7e8f9d55-ff6d-cbe7-e053-2a91aa0a382e"],"brand_name":["GUNA-HEMORRHOIDS"],"spl_set_id":["0fd0dcef-79c6-4489-a533-996aa5331d9c"],"package_ndc":["17089-296-18"],"product_ndc":["17089-296"],"generic_name":["ACTIVATED CHARCOAL - ARNICA MONTANA - ATROPA BELLADONNA - CANAKINUMAB - HYDROCOTYLE ASIATICA EXTRACT - AESCULUS HIPPOCASTANUM FLOWER - MELISSA OFFICINALIS - PAEONIA OFFICINALIS ROOT - PODOPHYLLUM PELTATUM ROOT - PORK LIVER - STRYCHNOS NUX-VOMICA SEED - SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE - SUS SCROFA VEIN - HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK - ANTI-INTERLEUKIN-1.ALPHA. IMMUNOGLOBULIN G RABBIT -"],"product_type":["HUMAN OTC DRUG"],"pharm_class_cs":["Allergens [CS]","Plant Proteins [CS]","Seed Storage Proteins [CS]"],"pharm_class_pe":["Increased Histamine Release [PE]","Cell-mediated Immunity [PE]","Increased IgG Production [PE]"],"substance_name":["ACTIVATED CHARCOAL","AESCULUS HIPPOCASTANUM FLOWER","ANTI-INTERLEUKIN-1.ALPHA. IMMUNOGLOBULIN G RABBIT","ARNICA MONTANA","ATROPA BELLADONNA","CANAKINUMAB","HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK","HYDROCOTYLE ASIATICA EXTRACT","MELISSA OFFICINALIS","PAEONIA OFFICINALIS ROOT","PODOPHYLLUM PELTATUM ROOT","PORK LIVER","STRYCHNOS NUX-VOMICA SEED","SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE","SUS SCROFA VEIN"],"pharm_class_epc":["Non-Standardized Plant Allergenic Extract [EPC]"],"manufacturer_name":["Guna spa"],"is_original_packager":[true]},"purpose":["USES Temporary relief of symptoms due to hemorrhoids such as: Pain Itching Burning"],"version":"2","warnings":["WARNINGS Stop use and ask doctor if symptoms persist more than 5 days. If pregnant or breast-feeding ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. Contains ethyl alcohol 30%"],"questions":["QUESTIONS Questions?: info@gunainc.com, tel. (484) 223-3500"],"effective_time":"20181221","active_ingredient":["ACTIVE INGREDIENTS/PURPOSE AESCULUS HIPPOCASTANUM 6C VENOUS FLOW SUPPORT ANTI INTERLEUKIN 1 ALPHA 4C IMMUNE STRENGTHENING ANTI INTERLEUKIN 1 BETA 4C IMMUNE STRENGTHENING ARNICA MONTANA 6C HEMORRHOIDAL ITCHING BELLADONNA 6C ANTI-INFLAMMATORY CARBO VEGETALIS 10X BOWEL DETOXIFICATION HAMAMELIS VIRGINIANA 6C HEMORRHOIDAL PAIN HEPAR 6X, 12X, 30X SUPPORTS LIVER DETOXIFICATION HYDROCOTYLE ASIATICA 6C PAIN RELIEF LYMPHATIC VESSEL 6X PROMOTES LYMPH FLOW MELISSA OFFICINALIS 6C DIGESTIVE NUX VOMICA 6C DIGESTIVE PAEONIA OFFICINALIS 6X ANTIHEMORRHOIDAL PODOPHYLLUM PELTATUM 4C BOWEL ACTIVITY VEIN 4C VENOUS FLOW SUPPORT"],"inactive_ingredient":["Inactive ingredient: Ethyl alcohol 30%."],"indications_and_usage":["Take 15 minutes before meals."],"dosage_and_administration":["DIRECTIONS Adults and children 12 years and older 20 drops in a little water, 2 times per day Children between 12 years and 6 years of age 10 drops in a little water, 2 times per day Children under 6 years 5 drops in a glass of water, 2 times per day"],"spl_product_data_elements":["GUNA-HEMORRHOIDS activated charcoal - arnica montana - atropa belladonna - canakinumab - hydrocotyle asiatica extract - aesculus hippocastanum flower - melissa officinalis - paeonia officinalis root - podophyllum peltatum root - pork liver - strychnos nux-vomica seed - sus scrofa small intestine mucosa lymph follicle - sus scrofa vein - hamamelis virginiana root bark/stem bark - anti-interleukin-1.alpha. immunoglobulin g rabbit - ALCOHOL AESCULUS HIPPOCASTANUM FLOWER AESCULUS HIPPOCASTANUM FLOWER ANTI-INTERLEUKIN-1.ALPHA. IMMUNOGLOBULIN G RABBIT ANTI-INTERLEUKIN-1.ALPHA. IMMUNOGLOBULIN G RABBIT CANAKINUMAB CANAKINUMAB ARNICA MONTANA ARNICA MONTANA ATROPA BELLADONNA ATROPA BELLADONNA ACTIVATED CHARCOAL ACTIVATED CHARCOAL HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK PORK LIVER PORK LIVER HYDROCOTYLE ASIATICA EXTRACT HYDROCOTYLE ASIATICA EXTRACT SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE MELISSA OFFICINALIS MELISSA OFFICINALIS STRYCHNOS NUX-VOMICA SEED STRYCHNOS NUX-VOMICA SEED PAEONIA OFFICINALIS ROOT PAEONIA OFFICINALIS ROOT PODOPHYLLUM PELTATUM ROOT PODOPHYLLUM PELTATUM ROOT SUS SCROFA VEIN SUS SCROFA VEIN"],"pregnancy_or_breast_feeding":["PREGNANCY If pregnant or breast-feeding ask a doctor before use."],"keep_out_of_reach_of_children":["WARNINGS Keep out of reach of children."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL 5USHEM-Rev03-02-05-18"]},"tags":[{"label":"Monoclonal Antibody","category":"modality"},{"label":"Interleukin-1 beta","category":"target"},{"label":"IL1B","category":"gene"},{"label":"L04AC08","category":"atc"},{"label":"Subcutaneous","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Articular gout","category":"indication"},{"label":"Cryopyrin associated periodic syndrome","category":"indication"},{"label":"Deficiency of mevalonate kinase","category":"indication"},{"label":"Familial Mediterranean fever","category":"indication"},{"label":"Systemic onset juvenile chronic arthritis","category":"indication"},{"label":"TNF receptor-associated periodic fever syndrome (TRAPS)","category":"indication"},{"label":"Novartis Pharms","category":"company"},{"label":"Approved 2000s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"1405 reports"},{"date":"","signal":"INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION","source":"FDA FAERS","actionTaken":"1242 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"1189 reports"},{"date":"","signal":"INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION","source":"FDA FAERS","actionTaken":"953 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"934 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"841 reports"},{"date":"","signal":"MALAISE","source":"FDA FAERS","actionTaken":"714 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"679 reports"},{"date":"","signal":"ARTHRALGIA","source":"FDA FAERS","actionTaken":"605 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"558 reports"}],"commonSideEffects":[{"effect":"Nasopharyngitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Influenza","drugRate":"","severity":"common","organSystem":""},{"effect":"Rhinitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Bronchitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Gastroenteritis","drugRate":"","severity":"common","organSystem":""},{"effect":"Pharyngitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Weight increased","drugRate":"","severity":"common","organSystem":""},{"effect":"Musculoskeletal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Vertigo","drugRate":"11.5%","severity":"common","organSystem":""},{"effect":"Injection-site reactions","drugRate":"9%","severity":"mild","organSystem":""}],"specialPopulations":{"Pregnancy":"Available human data from postmarketing experience and published case reports on ILARIS use in pregnant women are insufficient to identify drug-associated risk of major birth defects, miscarriage, and adverse maternal or fetal outcomes. Canakinumab, like other monoclonal antibodies, is actively transported across the placenta mainly during the third trimester of pregnancy and may cause immunosuppression in the in utero exposed infant (see Clinical Considerations).In animal embryo-fetal development studies with marmoset monkeys, there was no evidence of embryotoxicity or fetal malformations with subcutaneous administration of canakinumab during the period of organogenesis and later in gestation at doses that produced exposures approximately 11 times the exposure at the maximum recommended human dose (MRHD) and greater. Delays in fetal skeletal development were observed in marmoset monkeys following prenatal exposure to ILARIS at concentrations approximately 11 times the MRHD and greater. Similar delays in fetal skeletal development were observed in mice administered murine analog of ILARIS during the period of organogenesis. Delays in skeletal ossification are changes from the expected ossification state in an otherwise normal structure/bone: these findings are generally reversible or transitory and not detrimental to postnatal survival (see Animal Data).The estimated background risk of major birth defects and miscarriage is 2-4% and 15-20%, respectively; overall, approximately 50% of known pregnancies result in miscarriage. There are no controlled data in human pregnancy. The background risk of major birth defects and miscarriage for the indicated population is not known. Clinical ConsiderationsCanakinumab, like other monoclonal antibodies, is actively transported across the placenta mainly during the third trimester of pregnancy and may cause immunosuppression in the in utero exposed infant (see Clinical Considerations).","Geriatric use":"Clinical studies of ILARIS did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently from younger subjects.","Paediatric use":"The CAPS trials with ILARIS included total of 23 pediatric patients with an age range from years to 17 years (11 adolescents were treated subcutaneously with 150 mg, and 12 children were treated with mg/kg based on body weight greater than or equal to 15 kg and less than or equal to 40 kg). The majority of patients achieved improvement in clinical symptoms and objective markers of inflammation (e.g., Serum Amyloid [SAA] and C-Reactive Protein). Overall, the efficacy and safety of ILARIS in pediatric patients were similar to those observed in adult patients. The safety and efficacy of ILARIS in pediatric patients less than 2 years of age have not been established."},"seriousAdverseEvents":[{"effect":"Infections","drugRate":"","severity":"serious"},{"effect":"Intra-abdominal abscess","drugRate":"","severity":"serious"},{"effect":"Vertigo","drugRate":"1.92%","severity":"serious"}]},"trials":[],"aliases":[],"company":"Novartis Pharms","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CANAKINUMAB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:16:58.543735+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Canakinumab","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:17:10.817297+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:17:04.942567+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:16:58.567562+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:16:57.084248+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CANAKINUMAB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:17:05.664842+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:16:55.864286+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:16:55.864342+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:16:55.864351+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:17:11.742860+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Interleukin-1 beta inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:17:10.815865+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201834/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:17:10.716494+00:00"}},"allNames":"ilaris","offLabel":[],"synonyms":["canakinumab","ilaris","ACZ885"],"timeline":[{"date":"2009-06-17","type":"positive","source":"DrugCentral","milestone":"FDA approval (Novartis Pharms)"},{"date":"2009-10-23","type":"positive","source":"DrugCentral","milestone":"EMA approval"},{"date":"2011-09-26","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Novartis Pharma K.K.)"}],"aiSummary":"Ilaris (Canakinumab) is a biologic medication originally developed and currently owned by Novartis Pharmaceuticals. It targets interleukin-1 beta, a protein involved in inflammation, and is used to treat various inflammatory conditions, including gout, periodic fever syndromes, and juvenile arthritis. Ilaris is a monoclonal antibody, not a small molecule, and has been FDA-approved since 2009. It has a long half-life of 26 days, allowing for less frequent dosing. Ilaris is a patented medication with no generic manufacturers available.","brandName":"Ilaris","ecosystem":[{"indication":"Articular gout","otherDrugs":[{"name":"allopurinol","slug":"allopurinol","company":"Prometheus Labs"},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"cortisone acetate","slug":"cortisone-acetate","company":""}],"globalPrevalence":41000000},{"indication":"Cryopyrin associated periodic syndrome","otherDrugs":[{"name":"anakinra","slug":"anakinra","company":"Biovitrum Ab"},{"name":"rilonacept","slug":"rilonacept","company":"Regeneron Pharmaceuticals"}],"globalPrevalence":8800},{"indication":"Deficiency of mevalonate kinase","otherDrugs":[],"globalPrevalence":null},{"indication":"Familial Mediterranean fever","otherDrugs":[{"name":"anakinra","slug":"anakinra","company":"Biovitrum Ab"},{"name":"colchicine","slug":"colchicine","company":"Merck"}],"globalPrevalence":2000000000},{"indication":"Systemic onset juvenile chronic arthritis","otherDrugs":[],"globalPrevalence":null},{"indication":"TNF receptor-associated periodic fever syndrome (TRAPS)","otherDrugs":[],"globalPrevalence":2000000000}],"mechanism":{"target":"Interleukin-1 beta","novelty":"Follow-on","targets":[{"gene":"IL1B","source":"DrugCentral","target":"Interleukin-1 beta","protein":"Interleukin-1 beta"}],"modality":"Monoclonal Antibody","drugClass":"Non-Standardized Plant Allergenic Extract [EPC]","explanation":"","oneSentence":"","technicalDetail":"Ilaris is a human monoclonal antibody that selectively binds to human interleukin-1 beta with high affinity, thereby inhibiting its interaction with its receptor and subsequent inflammatory response."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Canakinumab","title":"Canakinumab","extract":"Canakinumab, sold under the brand name Ilaris, is a medication for the treatment of systemic juvenile idiopathic arthritis, active Still's disease, including adult-onset Still's disease, gout flares. It is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.","wiki_history":"== History ==\nCanakinumab was being developed by Novartis for the treatment of rheumatoid arthritis, but this trial was completed in October 2009. Canakinumab is also in phase I clinical trials as a possible treatment for chronic obstructive pulmonary disease, gout, and coronary artery disease (the CANTOS trial). It is also in trials for schizophrenia. In gout, it may result in better outcomes than a low dose of a steroid, but costs five thousand times more.\n\nIn August 2017, the results of the CANTOS trial were announced at the European Society of Cardiology. Those treated in CANTOS had a 15% reduction in deaths from heart attacks, stroke and cardiovascular disease combined. However, there were serious side-effects and no statistically significant overall survival benefit. Although the CANTOS study says, \"Overall, canakinumab was tolerated well with essentially identical discontinuation rates compared to placebo. Mild neutropenia and thrombocytopenia were slightly more common in those treated with canakinumab. Rates of death due to infection or sepsis were low but more likely in the canakinumab group compared to placebo (incidence rate 0.31 vs. 0.18 per 100 person-years, P = 0.02). In terms of the types of infections that occurred during follow up, only pseudomembranous colitis was more common in the canakinumab group; no evidence of opportunistic infection was observed, data emphasizing that canakinumab is not a clinically immunosuppressive intervention. Further demonstrating this issue, random allocation to canakinumab as compared to placebo in CANTOS resulted in large and highly significant dose-dependent reductions in cancer fatality, incident lung cancer, and fatal lung cancer.\" Nonetheless, David Goff, director of the division of cardiovascular sciences at the National Heart, Lung and Blood Institute feels the \"public health impact potential is really substantial,\" and estimates that in the United States 3 million people might benefit from canakinumab.\n\nIn Aug"},"commercial":{"launchDate":"2009","revenueYear":2025,"_launchSource":"DrugCentral (FDA 2009-06-17, NOVARTIS PHARMS)","annualRevenue":1369,"revenueSource":"Verified: Novartis 9M 2025","revenueCurrency":"USD","revenueConfidence":"verified","revenueExtractedAt":"2026-04-01T11:47:46.193324","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4952","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CANAKINUMAB","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CANAKINUMAB","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Canakinumab","fields":["history","overview"],"source":"Wikipedia"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T09:10:13.542766","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:17:13.453882+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"daclizumab","drugSlug":"daclizumab","fdaApproval":"1997-12-10","relationship":"same-class"},{"drugName":"basiliximab","drugSlug":"basiliximab","fdaApproval":"1998-05-12","relationship":"same-class"},{"drugName":"anakinra","drugSlug":"anakinra","fdaApproval":"2001-11-14","relationship":"same-class"},{"drugName":"rilonacept","drugSlug":"rilonacept","fdaApproval":"2008-02-27","relationship":"same-class"},{"drugName":"ustekinumab","drugSlug":"ustekinumab","fdaApproval":"2009-09-25","relationship":"same-class"},{"drugName":"tocilizumab","drugSlug":"tocilizumab","fdaApproval":"2010-01-08","relationship":"same-class"},{"drugName":"secukinumab","drugSlug":"secukinumab","fdaApproval":"2015-01-21","relationship":"same-class"},{"drugName":"siltuximab","drugSlug":"siltuximab","fdaApproval":"2014-04-23","relationship":"same-class"},{"drugName":"brodalumab","drugSlug":"brodalumab","fdaApproval":"2017-02-15","relationship":"same-class"},{"drugName":"ixekizumab","drugSlug":"ixekizumab","fdaApproval":"2016-03-22","relationship":"same-class"},{"drugName":"sarilumab","drugSlug":"sarilumab","fdaApproval":"2017-05-22","relationship":"same-class"},{"drugName":"guselkumab","drugSlug":"guselkumab","fdaApproval":"2017-07-13","relationship":"same-class"},{"drugName":"tildrakizumab","drugSlug":"tildrakizumab","fdaApproval":"2018-03-20","relationship":"same-class"},{"drugName":"risankizumab","drugSlug":"risankizumab","fdaApproval":"2019-04-23","relationship":"same-class"},{"drugName":"satralizumab","drugSlug":"satralizumab","fdaApproval":"2020-08-14","relationship":"same-class"},{"drugName":"spesolimab","drugSlug":"spesolimab","fdaApproval":"2022-09-01","relationship":"same-class"}],"genericName":"canakinumab","indications":{"approved":[{"name":"Articular gout","source":"DrugCentral","snomedId":48440001,"regulator":"FDA","usPrevalence":9200000,"globalPrevalence":41000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"},{"name":"Cryopyrin associated periodic syndrome","source":"DrugCentral","snomedId":430079001,"regulator":"FDA","usPrevalence":null,"globalPrevalence":8800,"prevalenceMethod":"curated","prevalenceSource":"Orphanet ([EXPERT]_17162528[PMID])"},{"name":"Deficiency of mevalonate kinase","source":"DrugCentral","snomedId":124327008,"regulator":"FDA"},{"name":"Familial Mediterranean fever","source":"DrugCentral","snomedId":12579009,"regulator":"FDA","usPrevalence":null,"globalPrevalence":2000000000,"prevalenceMethod":"curated","prevalenceSource":"Common symptom, not a disease"},{"name":"Systemic onset juvenile chronic arthritis","source":"DrugCentral","snomedId":201796004,"regulator":"FDA"},{"name":"TNF receptor-associated periodic fever syndrome (TRAPS)","source":"DrugCentral","snomedId":403833009,"regulator":"FDA","usPrevalence":null,"globalPrevalence":2000000000,"prevalenceMethod":"curated","prevalenceSource":"Common symptom, not a disease"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"daclizumab","brandName":"daclizumab","genericName":"daclizumab","approvalYear":"1997","relationship":"same-class"},{"drugId":"basiliximab","brandName":"basiliximab","genericName":"basiliximab","approvalYear":"1998","relationship":"same-class"},{"drugId":"anakinra","brandName":"anakinra","genericName":"anakinra","approvalYear":"2001","relationship":"same-class"},{"drugId":"rilonacept","brandName":"rilonacept","genericName":"rilonacept","approvalYear":"2008","relationship":"same-class"},{"drugId":"ustekinumab","brandName":"ustekinumab","genericName":"ustekinumab","approvalYear":"2009","relationship":"same-class"},{"drugId":"tocilizumab","brandName":"tocilizumab","genericName":"tocilizumab","approvalYear":"2010","relationship":"same-class"},{"drugId":"secukinumab","brandName":"secukinumab","genericName":"secukinumab","approvalYear":"2015","relationship":"same-class"},{"drugId":"siltuximab","brandName":"siltuximab","genericName":"siltuximab","approvalYear":"2014","relationship":"same-class"},{"drugId":"brodalumab","brandName":"brodalumab","genericName":"brodalumab","approvalYear":"2017","relationship":"same-class"},{"drugId":"ixekizumab","brandName":"ixekizumab","genericName":"ixekizumab","approvalYear":"2016","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04717635","phase":"PHASE3","title":"Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-03-30","conditions":["Adult Onset Still's Disease"],"enrollment":14,"completionDate":"2025-04-16"},{"nctId":"NCT05467800","phase":"PHASE2","title":"Study of Canakinumab in Patients With Myelofibrosis","status":"RECRUITING","sponsor":"John Mascarenhas","startDate":"2022-08-02","conditions":["Primary Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis","ET-MF","Post-polycythemia Vera Related Myelofibrosis","PV-MF"],"enrollment":14,"completionDate":"2027-07-01"},{"nctId":"NCT06724562","phase":"","title":"IL1 Inhibition in FOP","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-04-01","conditions":["Fibrodysplasia Ossificans Progressiva (FOP)"],"enrollment":11,"completionDate":"2027-03"},{"nctId":"NCT03631199","phase":"PHASE3","title":"Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-21","conditions":["Non-small Cell Lung Cancer"],"enrollment":673,"completionDate":"2026-01-26"},{"nctId":"NCT06038526","phase":"PHASE2","title":"Evaluation of Canakinumab in High-Risk Former-Smokers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter Shields","startDate":"2024-03-11","conditions":["Cigarette Smoking-Related Carcinoma","Lung Carcinoma"],"enrollment":41,"completionDate":"2026-07-31"},{"nctId":"NCT06691217","phase":"PHASE2","title":"Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-02-16","conditions":["Vascular Inflammation","ASCVD","ASCVD Management"],"enrollment":120,"completionDate":"2030-04-01"},{"nctId":"NCT02961218","phase":"PHASE2","title":"Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-04-05","conditions":["Sickle Cell Anemia"],"enrollment":49,"completionDate":"2020-04-27"},{"nctId":"NCT05641831","phase":"PHASE2","title":"Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study","status":"RECRUITING","sponsor":"Uma Borate","startDate":"2023-02-06","conditions":["Clonal Cytopenia of Undetermined Significance"],"enrollment":110,"completionDate":"2028-12-31"},{"nctId":"NCT06838143","phase":"","title":"Ilaris NIS in Korea","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-03-29","conditions":["Hereditary Periodic Fever Syndromes","Cryopyrin-associated Periodic Syndromes (CAPS)","Colchicine Resistance Familial Mediterranean Fever (crFMF)","TNF Receptor Associated Periodic Syndrome (TRAPS)","Hyper-IgD Syndrome / Mevalonate Kinase Deficiency (HIDS/MKD)","Systemic Juvenile Idiopathic Arthritis (sJIA)"],"enrollment":25,"completionDate":"2028-09-30"},{"nctId":"NCT04789681","phase":"PHASE2","title":"Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-07-20","conditions":["Lung Carcinoma","Stage I Lung Cancer AJCC v8","Stage IA1 Lung Cancer AJCC v8","Stage IA2 Lung Cancer AJCC v8","Stage IA3 Lung Cancer AJCC v8","Stage IB Lung Cancer AJCC v8","Stage II Lung Cancer AJCC v8","Stage IIA Lung Cancer AJCC v8","Stage IIB Lung Cancer AJCC v8","Stage III Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8"],"enrollment":50,"completionDate":"2027-12-31"},{"nctId":"NCT04239157","phase":"PHASE2","title":"A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-25","conditions":["Chronic Myelomonocytic Leukemia","Myelodysplastic Syndrome","Recurrent Chronic Myelomonocytic Leukemia","Recurrent Myelodysplastic Syndrome","Refractory Chronic Myelomonocytic Leukemia","Refractory Myelodysplastic Syndrome"],"enrollment":76,"completionDate":"2026-12-31"},{"nctId":"NCT05535738","phase":"PHASE2,PHASE3","title":"Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation","status":"RECRUITING","sponsor":"Wei-Che Ko","startDate":"2022-11-15","conditions":["Skin Inflammation","Allergic Contact Dermatitis"],"enrollment":45,"completionDate":"2027-12-31"},{"nctId":"NCT04798339","phase":"PHASE1,PHASE2","title":"Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-03-30","conditions":["Myelodysplastic Syndromes"],"enrollment":13,"completionDate":"2026-07"},{"nctId":"NCT04814368","phase":"PHASE2","title":"A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-08-27","conditions":["Knee Osteoarthritis"],"enrollment":23,"completionDate":"2024-06-24"},{"nctId":"NCT04795466","phase":"PHASE2","title":"Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-28","conditions":["Mild Cognitive Impairment","Alzheimer Disease"],"enrollment":34,"completionDate":"2024-03-07"},{"nctId":"NCT04810611","phase":"PHASE1","title":"Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-18","conditions":["Myelodysplastic Syndromes"],"enrollment":33,"completionDate":"2024-04-19"},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":["Rheumatic Disease"],"enrollment":80,"completionDate":"2027-09"},{"nctId":"NCT06497491","phase":"PHASE3","title":"An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still&#39;s Disease","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2023-12-12","conditions":["Still's Disease Adult Onset"],"enrollment":118,"completionDate":"2025-07-10"},{"nctId":"NCT04028245","phase":"EARLY_PHASE1","title":"A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Columbia University","startDate":"2019-08-15","conditions":["Carcinoma, Renal Cell"],"enrollment":17,"completionDate":"2026-03"},{"nctId":"NCT04905316","phase":"PHASE2","title":"A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-05-21","conditions":["Non-small Cell Lung Cancer"],"enrollment":41,"completionDate":"2026-05"},{"nctId":"NCT03742349","phase":"PHASE1","title":"Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-01-31","conditions":["Triple Negative Breast Cancer (TNBC)"],"enrollment":64,"completionDate":"2023-02-06"},{"nctId":"NCT04581343","phase":"PHASE1","title":"A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients","status":"COMPLETED","sponsor":"Pancreatic Cancer Action Network","startDate":"2020-11-02","conditions":["Metastatic Pancreatic Ductal Adenocarcinoma"],"enrollment":10,"completionDate":"2023-02-27"},{"nctId":"NCT05080218","phase":"PHASE4","title":"COVID-19 VaccinE Response in Rheumatology Patients","status":"COMPLETED","sponsor":"Jeffrey Curtis","startDate":"2021-11-15","conditions":["Rheumatoid Arthritis","Psoriatic Arthritis","Spondylarthritis"],"enrollment":841,"completionDate":"2024-05-28"},{"nctId":"NCT01731990","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10-30","conditions":["Peripheral Artery Disease"],"enrollment":38,"completionDate":"2016-08-04"},{"nctId":"NCT05984602","phase":"PHASE1","title":"A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2023-07-14","conditions":["Pancreatic Cancer"],"enrollment":10,"completionDate":"2026-01-01"},{"nctId":"NCT04229004","phase":"PHASE3","title":"A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Pancreatic Cancer Action Network","startDate":"2020-01-31","conditions":["Metastatic Pancreatic Cancer","Metastatic Pancreatic Adenocarcinoma"],"enrollment":502,"completionDate":"2025-02-05"},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":["Coronavirus Infection (COVID-19)","Pulmonary Arterial Hypertension","Urinary Tract Infections in Children","Hypertension","Pain","Hyperphosphatemia","Primary Hyperaldosteronism","Edema","Hypokalemia","Heart Failure","Hemophilia","Menorrhagia","Insomnia","Pneumonia","Skin Infection","Arrythmia","Asthma in Children","Bronchopulmonary Dysplasia","Adrenal Insufficiency","Fibrinolysis; Hemorrhage","Attention Deficit Hyperactivity Disorder","Multisystem Inflammatory Syndrome in Children (MIS-C)","Kawasaki Disease","Coagulation Disorder","Down Syndrome"],"enrollment":5000,"completionDate":"2027-09"},{"nctId":"NCT03775109","phase":"PHASE2","title":"IL-1 Signal Inhibition in Alcoholic Hepatitis","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2019-02-12","conditions":["Alcoholic Hepatitis"],"enrollment":55,"completionDate":"2023-03-31"},{"nctId":"NCT05401578","phase":"PHASE3","title":"Canakinumab for the Treatment of Postprandial Hypoglycemia","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2023-04-17","conditions":["Postprandial Hypoglycemia"],"enrollment":56,"completionDate":"2026-05-31"},{"nctId":"NCT03447769","phase":"PHASE3","title":"Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-03-16","conditions":["Non-Small Cell Lung Cancer"],"enrollment":1382,"completionDate":"2023-02-07"},{"nctId":"NCT06481189","phase":"PHASE1","title":"A Safety, Pharmacokinetics and Pharmacodynamics Study of GNR-086 and Ilaris® in Healthy Volunteers","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2022-09-06","conditions":["Healthy Volunteers"],"enrollment":105,"completionDate":"2023-05-26"},{"nctId":"NCT03968419","phase":"PHASE2","title":"This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-11-05","conditions":["Non-small Cell Lung Cancer"],"enrollment":88,"completionDate":"2022-08-15"},{"nctId":"NCT03484923","phase":"PHASE2","title":"Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-09-10","conditions":["Melanoma"],"enrollment":196,"completionDate":"2022-12-30"},{"nctId":"NCT05237713","phase":"PHASE2","title":"Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients","status":"TERMINATED","sponsor":"University of Leipzig","startDate":"2022-04-26","conditions":["Anemia","Myelodysplastic Syndromes"],"enrollment":10,"completionDate":"2024-02-29"},{"nctId":"NCT03936894","phase":"PHASE1,PHASE2","title":"Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) in Duchenne Muscular Dystrophy","status":"UNKNOWN","sponsor":"Children's National Research Institute","startDate":"2019-05-01","conditions":["Duchenne Muscular Dystrophy"],"enrollment":3,"completionDate":"2024-04"},{"nctId":"NCT03626545","phase":"PHASE3","title":"Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-01-23","conditions":["Non-Small-Cell Lung"],"enrollment":245,"completionDate":"2021-12-20"},{"nctId":"NCT05964946","phase":"","title":"Real-life Study of the Characteristics of Patients Treated With Ilaris® (Canakinumab) for Gouty Arthritis in France","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-24","conditions":["Gouty Arthritis"],"enrollment":15,"completionDate":"2022-07-29"},{"nctId":"NCT04348448","phase":"","title":"Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia","status":"TERMINATED","sponsor":"AUSL Romagna Rimini","startDate":"2020-02-01","conditions":["COVID-19"],"enrollment":100,"completionDate":"2020-09-01"},{"nctId":"NCT02272946","phase":"PHASE2","title":"Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk","status":"COMPLETED","sponsor":"Priscilla Hsue, MD","startDate":"2015-09","conditions":["HIV","Cardiovascular Disease"],"enrollment":43,"completionDate":"2021-12"},{"nctId":"NCT05725343","phase":"PHASE3","title":"A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2022-02-03","conditions":["Lung Cancer"],"enrollment":350,"completionDate":"2022-09-21"},{"nctId":"NCT03064854","phase":"PHASE1","title":"PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-05-24","conditions":["Non-small Cell Lung Cancer"],"enrollment":111,"completionDate":"2021-07-28"},{"nctId":"NCT04821414","phase":"","title":"Effects of IL-1β and Its Receptor Antagonists in the Treatment of Severe Infection and Inflammatory Storm in Children","status":"WITHDRAWN","sponsor":"Children's Hospital of Fudan University","startDate":"2022-09-01","conditions":["Critical Illness","Sepsis, Severe"],"enrollment":0,"completionDate":"2024-12-31"},{"nctId":"NCT02900664","phase":"PHASE1","title":"A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-08-23","conditions":["Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma"],"enrollment":283,"completionDate":"2021-03-17"},{"nctId":"NCT04362813","phase":"PHASE3","title":"Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-04-30","conditions":["Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia"],"enrollment":454,"completionDate":"2020-12-22"},{"nctId":"NCT02888080","phase":"PHASE2","title":"Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-12-19","conditions":["Pulmonary Sarcoidosis"],"enrollment":40,"completionDate":"2019-03-04"},{"nctId":"NCT01364389","phase":"PHASE2","title":"A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-02-14","conditions":["Polymyalgia Rheumatica","Inflammatory Diseases"],"enrollment":16,"completionDate":"2013-01-29"},{"nctId":"NCT04510493","phase":"PHASE3","title":"Canakinumab in Patients With COVID-19 and Type 2 Diabetes","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-10-23","conditions":["Coronavirus Infection","Diabetes Mellitus, Type 2"],"enrollment":116,"completionDate":"2021-08-17"},{"nctId":"NCT01431638","phase":"PHASE3","title":"Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-08-25","conditions":["Acute Gouty Arthritis"],"enrollment":397,"completionDate":"2013-05-09"},{"nctId":"NCT00554606","phase":"PHASE2","title":"Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-10-11","conditions":["Rheumatoid Arthritis"],"enrollment":115,"completionDate":"2009-08-13"},{"nctId":"NCT01470989","phase":"PHASE3","title":"β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-11","conditions":["Acute Gouty Arthritis Flares"],"enrollment":136,"completionDate":"2013-05"},{"nctId":"NCT00927810","phase":"PHASE2","title":"Long Term Study of Canakinumab (ACZ885) in Patients With Gout","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-06-05","conditions":["Gouty Arthritis"],"enrollment":341,"completionDate":"2010-08-04"},{"nctId":"NCT00770601","phase":"PHASE3","title":"Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-01-26","conditions":["NOMID","CINCA Syndrome"],"enrollment":7,"completionDate":"2011-02-17"},{"nctId":"NCT04365153","phase":"PHASE2","title":"Canakinumab in Covid-19 Cardiac Injury (The Three C Study)","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2020-04-24","conditions":["COVID-19","SARS-CoV 2"],"enrollment":45,"completionDate":"2021-04-01"},{"nctId":"NCT04476706","phase":"","title":"Canakinumab MAP in COVID-19 Pneumonia With CRS","status":"NO_LONGER_AVAILABLE","sponsor":"Novartis Pharmaceuticals","startDate":"","conditions":["Cytokine Release Syndrome in COVID-19-induced Pneumonia"],"enrollment":0,"completionDate":""},{"nctId":"NCT02007252","phase":"PHASE2","title":"ACZ885 for the Treatment of Abdominal Aortic Aneurysm","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12","conditions":["Abdominal Aortic Aneurysm (AAA)"],"enrollment":65,"completionDate":"2015-10"},{"nctId":"NCT00991146","phase":"PHASE3","title":"Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-10","conditions":["Cryopyrin-associated Periodic Syndromes","Familial Cold Autoinflammatory Syndrome","Muckle-Wells Syndrome","Neonatal Onset Multisystem Inflammatory Disease"],"enrollment":19,"completionDate":"2012-02"},{"nctId":"NCT02204293","phase":"PHASE2","title":"Canakinumab for Treatment of Adult-onset Still's Disease","status":"TERMINATED","sponsor":"Charite University, Berlin, Germany","startDate":"2012-06-21","conditions":["Adult-Onset Still´s Disease"],"enrollment":36,"completionDate":"2018-05-05"},{"nctId":"NCT02756650","phase":"PHASE2","title":"1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-06-23","conditions":["Behcet Disease"],"enrollment":8,"completionDate":"2019-01-31"},{"nctId":"NCT02334748","phase":"PHASE3","title":"A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-11-03","conditions":["Systemic Juvenile Idiopathic Arthritis","Hereditary Periodic Fevers"],"enrollment":31,"completionDate":"2018-08-31"},{"nctId":"NCT00947427","phase":"PHASE2","title":"Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2010-10","conditions":["Type 1 Diabetes","Preservation of Insulin Secretion","Newly Diagnosed Type 1 Diabetes","Canakinumab in Type 1 Diabetes"],"enrollment":71,"completionDate":"2013-04"},{"nctId":"NCT01327846","phase":"PHASE3","title":"Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-04-11","conditions":["Atherosclerosis"],"enrollment":10066,"completionDate":"2019-04-14"},{"nctId":"NCT02396212","phase":"PHASE3","title":"Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05-07","conditions":["Systemic Juvenile Idiopathic Arthritis"],"enrollment":19,"completionDate":"2018-08-01"},{"nctId":"NCT02296424","phase":"PHASE3","title":"ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-11-17","conditions":["Systemic Juvenile Idiopathic Arthritis (SJIA)"],"enrollment":182,"completionDate":"2017-09-25"},{"nctId":"NCT01245127","phase":"PHASE2","title":"Ilaris (Canakinumab) in the Schnitzler Syndrome","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2011-05","conditions":["Schnitzler Syndrome"],"enrollment":1,"completionDate":"2012-05"},{"nctId":"NCT00891046","phase":"PHASE3","title":"An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-09","conditions":["Systemic Juvenile Idiopathic Arthritis"],"enrollment":270,"completionDate":"2014-12"},{"nctId":"NCT01900600","phase":"NA","title":"Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated High Sensitivity C-reactive Protein (Hs-CRP)","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2013-04","conditions":["Prior Acute Myocardial Infarction","Evidence of Systemic Inflammation (C Reactive Protein Plasma >2 mg/l)","Reduced Left Ventricle Ejection Fraction (<50%)","Symptoms of Heart Failure (NYHA Class II-III)"],"enrollment":15,"completionDate":"2015-01-08"},{"nctId":"NCT01576367","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-01-16","conditions":["Cryopyrin-associated Periodic Syndromes","Familial Cold Autoinflammatory Syndrome","Muckle-Wells Syndrome","Neonatal Onset Multisystem Inflammatory Disease"],"enrollment":17,"completionDate":"2015-10-13"},{"nctId":"NCT02775994","phase":"PHASE1","title":"Ilaris (Canakinumab) in Patient With Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA)","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2016-08","conditions":["Periodic Fever"],"enrollment":10,"completionDate":"2020-03"},{"nctId":"NCT02911857","phase":"PHASE3","title":"An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-10-03","conditions":["Periodic Fevers Syndrome"],"enrollment":4,"completionDate":"2017-01-27"},{"nctId":"NCT01390350","phase":"PHASE2","title":"Ilaris® Effects in Schnitzler Syndrome (ILESCH)","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2011-07","conditions":["Schnitzler Syndrome"],"enrollment":20,"completionDate":"2018-05"},{"nctId":"NCT00819585","phase":"PHASE2","title":"A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-12","conditions":["Gout"],"enrollment":432,"completionDate":"2010-08"},{"nctId":"NCT02059291","phase":"PHASE3","title":"Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-06-27","conditions":["Hereditary Periodic Fevers"],"enrollment":203,"completionDate":"2017-07-04"},{"nctId":"NCT00465985","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-04","conditions":["Muckle Wells Syndrome"],"enrollment":35,"completionDate":""},{"nctId":"NCT01362608","phase":"PHASE3","title":"Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-06-20","conditions":["Gouty Arthritis"],"enrollment":136,"completionDate":"2015-05-19"},{"nctId":"NCT01593527","phase":"PHASE3","title":"Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2012-09","conditions":["Acute Gouty Arthritis"],"enrollment":0,"completionDate":"2012-09"},{"nctId":"NCT01302860","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-11","conditions":["Cryopyrin-associated Periodic Syndromes","Familial Cold Autoinflammatory Syndrome","Muckle-Wells Syndrome","Neonatal Onset Multisystem Inflammatory Disease"],"enrollment":17,"completionDate":"2014-11"},{"nctId":"NCT00886769","phase":"PHASE3","title":"Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-07","conditions":["Systemic Juvenile Idiopathic Arthritis"],"enrollment":84,"completionDate":"2011-01"},{"nctId":"NCT01105507","phase":"PHASE3","title":"The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-08","conditions":["Cryopyrin Associated Periodic Syndrome"],"enrollment":4,"completionDate":"2012-05-12"},{"nctId":"NCT02980263","phase":"PHASE2","title":"Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2016-11-15","conditions":["Kawasaki Disease"],"enrollment":0,"completionDate":"2017-11-30"},{"nctId":"NCT01805960","phase":"PHASE2","title":"Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF","status":"TERMINATED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2013-06","conditions":["Atrial Fibrillation"],"enrollment":24,"completionDate":"2016-12"},{"nctId":"NCT01148797","phase":"PHASE2","title":"Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-12","conditions":["Colchicine Resistant/Intolerant Familial Mediterranean Fever"],"enrollment":15,"completionDate":""},{"nctId":"NCT00685373","phase":"PHASE3","title":"Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-05","conditions":["Cryopyrin-Associated Periodic Syndromes","Familial Cold Autoinflammatory Syndrome","Muckle Wells Syndrome","Neonatal Onset Multisystem Inflammatory Disease"],"enrollment":166,"completionDate":"2010-04"},{"nctId":"NCT01302795","phase":"PHASE2","title":"Canakinumab for Pyoderma Gangrenosum","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2011-02","conditions":["Pyoderma Gangrenosum"],"enrollment":5,"completionDate":"2015-11"},{"nctId":"NCT01635127","phase":"PHASE2","title":"Efficacy Study of Canakinumab to Treat Urticaria","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2012-06","conditions":["Chronic Idiopathic Urticaria"],"enrollment":20,"completionDate":"2017-05"},{"nctId":"NCT01213641","phase":"","title":"Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-11","conditions":["Cryopyrin-associated Periodic Syndromes (CAPS)","Familial Cold Autoinflam Syn (FCAS)","Muckle-wells Syn (MWS)","Neonatal Onset Multisystem Inflam Disease (NOMID)"],"enrollment":288,"completionDate":"2015-12"},{"nctId":"NCT01242813","phase":"PHASE2","title":"Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-10","conditions":["TNF-receptor Associated Periodic Syndromes (TRAPS)"],"enrollment":20,"completionDate":"2014-06"},{"nctId":"NCT01589029","phase":"PHASE1","title":"A Pilot Study on the Effects of ILARIS® on Patients With Proliferative Diabetic Retinopathy (PDRP)","status":"TERMINATED","sponsor":"PD Dr. med. Stephan Michels","startDate":"2012-04","conditions":["Proliferative Diabetic Retinopathy"],"enrollment":6,"completionDate":"2014-11"},{"nctId":"NCT01303380","phase":"PHASE2","title":"Canakinumab in Patients With Active Hyper-IgD Syndrome","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-03","conditions":["Mevalonate Kinase Deficiency"],"enrollment":9,"completionDate":"2014-07"},{"nctId":"NCT01676948","phase":"PHASE3","title":"An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2013-01","conditions":["Systemic Juvenile Idiopathic Arthritis"],"enrollment":0,"completionDate":"2015-01"},{"nctId":"NCT00995930","phase":"PHASE2","title":"Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-12","conditions":["Diabetes Mellitus, Type 2","Atherosclerosis","Prediabetic State"],"enrollment":189,"completionDate":"2014-02"},{"nctId":"NCT00424346","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-11","conditions":["Rheumatoid Arthritis"],"enrollment":274,"completionDate":"2009-10"},{"nctId":"NCT01080131","phase":"PHASE3","title":"Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-03","conditions":["Acute Gout"],"enrollment":226,"completionDate":"2011-10"},{"nctId":"NCT01029652","phase":"PHASE3","title":"Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-12","conditions":["Acute Gout"],"enrollment":230,"completionDate":"2010-10"},{"nctId":"NCT01356602","phase":"PHASE3","title":"Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-05","conditions":["Acute Gouty Arthritis"],"enrollment":397,"completionDate":"2012-09"},{"nctId":"NCT00663169","phase":"PHASE2","title":"Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-04","conditions":["Arthritis, Gouty"],"enrollment":6,"completionDate":"2009-10"},{"nctId":"NCT01250171","phase":"PHASE2","title":"The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-11","conditions":["Dry Eye"],"enrollment":72,"completionDate":"2011-09"},{"nctId":"NCT01160822","phase":"PHASE2","title":"To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-04","conditions":["Osteoarthritis"],"enrollment":169,"completionDate":"2011-07"},{"nctId":"NCT00889863","phase":"PHASE3","title":"Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-07","conditions":["Systemic Juvenile Idiopathic Arthritis With Active Flare"],"enrollment":177,"completionDate":"2011-09"},{"nctId":"NCT01322321","phase":"PHASE2","title":"ACZ885 in Type 1 Diabetes Mellitus","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2011-03","conditions":["Diabetes Mellitus","Diabetes Type 1"],"enrollment":0,"completionDate":""},{"nctId":"NCT00504595","phase":"PHASE2","title":"Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-05","conditions":["Rheumatoid Arthritis"],"enrollment":80,"completionDate":"2008-09"}],"_emaApprovals":[{"date":"2009-10-23","status":"Authorised","company":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Injection","formulations":[{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Ilaris"}]},"crossReferences":{"NUI":"N0000178497","MMSL":"165731","NDDF":"013212","UNII":"37CQ2C7X93","VUID":"4028805","VANDF":"4028805","INN_ID":"8836","RXNORM":"853491","UMLSCUI":"C2718773","chemblId":"CHEMBL1201834","ChEMBL_ID":"CHEMBL1201834","KEGG_DRUG":"D09315","DRUGBANK_ID":"DB06168","SNOMEDCT_US":"698091001","IUPHAR_LIGAND_ID":"6773","MESH_SUPPLEMENTAL_RECORD_UI":"C541220"},"formularyStatus":[],"originalProduct":{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","company":"Novartis Pharmaceuticals Corporation","brandName":"Ilaris","isOriginal":true,"marketingStatus":"BLA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2009-","companyName":"Novartis Pharms","relationship":"Original Developer"},{"period":"2011","companyName":"Novartis Pharma K.K.","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"FDA label","halfLife":"26 days"},"publicationCount":1220,"therapeuticAreas":["Immunology"],"_revenueScrapedAt":"2026-04-08 13:58:35.671847+00","atcClassification":{"source":"DrugCentral","atcCode":"L04AC08","allCodes":["L04AC08"]},"biosimilarFilings":[],"originalDeveloper":"Novartis Pharms","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Novartis Pharms","companyId":"novartis","modality":"Monoclonal antibody","firstApprovalDate":"2009","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-09-23T00:00:00.000Z","mah":"NOVARTIS PHARMS","brand_name_local":null,"application_number":"BLA125319"},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":15,"withResults":4},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:17:13.453882+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}